Dr Chichagova awarded best In Vitro Toxicology Society poster
This year’s British Toxicology Society Congress 2018 saw the IVTS Poster Prize awarded to our own Dr Valeria Chichagova, for her work in human retina models.
British Toxicological Society Annual Congress 2018 – Hilton Gateshead (16th-18th April)
The Newcells Biotech team will be attending the British Toxicological Society Annual Congress 2018 that is taking place in Gateshead on 16th-18th April.
Newcells Biotech to develop 3D retinal organoids using hiPSC derived skin cells
Newcells Biotech in partnership with Newcastle University has been awarded further funding from the NC3R CRACK IT project to create 3D retinal organoids that more closely recapitulate the structure and function of the human retina.
Current cell-based screens are poor models of human biology
Current cell assays for in vitro screening are based on genetically modified cell lines which are crude models of human biology.
hiPSCs derived cells in disease modelling
The discovery in 2007 that cells isolated from mature human tissues can be reprogrammed into cells that show pluripotency was a major breakthrough in stem cell science.
Renal drug handing and drug-drug interactions in ADMET
Led by Dr Colin Brown, Newcells Biotech has licensed-in an in vitro ADMET assay platform from Newcastle University to determine how new drugs are transported by the kidney.
Newcells Biotech joins StemBANCC consortium
Newcells Biotech has joined the StemBANCC project, a pan-EU consortium made up of major pharmaceutical and academe groups.
Development of iPSC derived Conducting Airways and application to toxicity testing
Newcells Biotech have been awarded a grant to employ a PhD student to help develop models of the human lung from iPSCs.
Newcells Biotech to develop a new skin metabolism model using iPSC derived skin cells
Newcells Biotech has been successful in partnering with Newcastle University to receive funding in a £100K phase I NC3R CRACK IT project to develop a new skin metabolism model using iPSC derived skin cells.
Newcells Biotech Ltd completes a licensing agreement with ID Pharma Co. Ltd for induced pluripotent stem cell technologies
Newcells Biotech Ltd has signed a patent license agreement with ID Pharma Co., Ltd to license and commercialise ID Pharma Co., Ltd patented technologies in the Sendai virus vectors for reprogramming cells to induced pluripotent stem cells (iPSCs).
Newcells Biotech Ltd completes a licensing agreement with iPS Academia Japan, Inc. for induced pluripotent stem cell technologies
Newcells Biotech Ltd has signed a patent license agreement with iPS Academia Japan, Inc. to license and commercialise Kyoto University’s patented technologies in the field of induced pluripotent stem cells (iPSCs).
